Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

Novo Nordisk disclosed top-line Phase II data in NASH for semaglutide that puts the GLP-1 agonist in pole position with respect to mechanisms addressing NASH resolution.

The readout came as Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced strong growth in 1Q20 due to COVID-19-related stockpiling.

Novo said

Read the full 474 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE